目的 探讨滑膜炎片联合尼美舒利治疗膝关节滑膜炎的临床疗效。方法 选取2021年11月—2023年12月廊坊市人民医院收治的膝关节滑膜炎100例，依据用药情况分为对照组（50例）和治疗组（50例）。对照组患者口服尼美舒利分散片，0.1 g/次，2次/d。在对照组的基础上，治疗组口服滑膜炎片，3片/次，3次/d。两组治疗15 d。观察两组患者临床疗效，比较治疗前后两组患者症状好转时间，疼痛视觉模拟评分量表（VAS）、Lysholm膝关节功能评分量表（LKSS）和生活质量健康状况调查评分表（SF-36）评分，及血清基质金属蛋白酶-3（MMP-3）、肿瘤坏死因子-α（TNF-α）、前列腺素E₂（PGE₂）和白细胞介素-1β（IL-1β）水平。结果 治疗后，治疗组临床总有效率为94.00%，明显高于对照组的82.00%（P＜0.05）。治疗后，治疗组患者膝关节肿胀、膝关节疼痛、膝关节活动受限等症状好转时间均明显早于对照组（P＜0.05）。治疗后，两组患者LKSS评分和ST-36评分明显高于治疗前，而VAS评分明显低于治疗前（P＜0.05），且治疗组患者评分明显好于对照组（P＜0.05）。治疗后，两组患者血清IL-1β、MMP-3、PGE₂、TNF-α水平明显降低（P＜0.05），且治疗组明显低于对照组（P＜0.05）。结论 尼美舒利与滑膜炎片协同治疗，能较快的纠正临床症状状态，膝关节活动功能提升明显，局部炎症反应减弱，生活质量显著增强，且安全有效。

Objective To explore the clinical effect of Huamoyan Tablets combined with nimesulide in treatment of knee synovitis. Methods Patients (100 cases) with knee synovitis in the People’s Hospital of Langfang City from November 2021 to December 2023 were divided into control (50 cases) and treatment (50 cases) group based on different treatments. Patients in the control group were po administered with Nimesulide Dispersible Tablets, 0.1 g/time, twice daily. Patients in the treatment group were po administered with Huamoyan Tablets on the basis of the control group, 3 tablets/time, three times daily. Patients in two groups were treated for 15 d. After treatment, the clinical evaluations were evaluated, the symptom relief time, the scores of LKSS, VAS and ST-36, and the levels of serum IL-1β, MMP-3, PGE₂ and TNF-α in two groups before and after treatment were compared. Results After treatment, the clinical effective rate of the treatment group was 94.00%, which was significantly higher than 82.00% of the control group (P < 0.05). After treatment, the improvement time of symptoms such as knee joint swelling, knee joint pain, and limited knee joint movement in the treatment group was significantly earlier than that in the control group (P < 0.05). After treatment, the LKSS score and ST-36 score in two groups were significantly higher than before treatment, while the VAS score was significantly lower than before treatment (P < 0.05), and the scores in the treatment group were significantly better than those of the control group (P < 0.05). After treatment, the levels of serum IL-1β, MMP-3, TNF-α, and PGE₂ in two groups were significantly reduced (P < 0.05), and which in the treatment group were significantly lower than that in the control group (P < 0.05). Conclusion The synergistic treatment of nimesulide and Huamoyan Tablets can quickly correct clinical symptoms, significantly improve knee joint mobility, which can reduce local inflammatory reactions, significantly enhance quality of life, and is safe and effective.

R977